Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2003 Jun;62(6):526–529. doi: 10.1136/ard.62.6.526

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

L Padyukov 1, J Lampa 1, M Heimburger 1, S Ernestam 1, T Cederholm 1, I Lundkvist 1, P Andersson 1, Y Hermansson 1, A Harju 1, L Klareskog 1, J Bratt 1
PMCID: PMC1754569  PMID: 12759288

Abstract

Background: Rheumatoid arthritis (RA) is a genetically complex disease where the response to different treatments varies greatly between different patients. This is the case with the tumour necrosis factor (TNF) blocking agents, where 20–40% of patients have been described as non-responders. No predictive markers exist as yet for the prognosis of response.

Objective: To analyse whether polymorphisms of several cytokine genes are associated with the responsiveness to TNF blockade with etanercept.

Methods: 123 patients with active RA were treated with etanercept and response rates were determined after three months using American College of Rheumatology (ACR)20 and disease activity score (DAS)28 response criteria. Genotyping was done for TNF (-308 TNFA), interleukin (IL)10 (-1087 IL10), transforming growth factor (TGF)ß1 (codon 25 TGFB1), and IL1 receptor antagonist (intron 2 IL1RN).

Results: 24 patients (20%) were defined as non-responders owing to their failure to fulfil any of the ACR20 or DAS28 response criteria. None of the recorded alleles was alone significantly associated with responsiveness to treatment. However, a certain combination of alleles (-308 TNF1/TNF1 and -1087 G/G) was associated with good responsiveness to etanercept (p<0.05). In addition, a combination of alleles influencing interleukin 1 receptor antagonist (IL1Ra) and TGFß1 production (A2 allele for IL1RN and rare C allele in codon 25 of TGFB1 gene) was associated with non-responsiveness (p<0.05).

Conclusion: Genetic polymorphisms, which may influence the balance of pro- and anti-inflammatory cytokines of relevance for the course of RA, are associated with clinical responsiveness to etanercept treatment.

Full Text

The Full Text of this article is available as a PDF (99.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aldener-Cannavá A., Olerup O. HLA-DPA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) and distribution of DPA1 alleles in Caucasian, African and Oriental populations. Tissue Antigens. 1996 Sep;48(3):153–160. doi: 10.1111/j.1399-0039.1996.tb02623.x. [DOI] [PubMed] [Google Scholar]
  2. Arnett F. C., Edworthy S. M., Bloch D. A., McShane D. J., Fries J. F., Cooper N. S., Healey L. A., Kaplan S. R., Liang M. H., Luthra H. S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–324. doi: 10.1002/art.1780310302. [DOI] [PubMed] [Google Scholar]
  3. Awad M. R., El-Gamel A., Hasleton P., Turner D. M., Sinnott P. J., Hutchinson I. V. Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation. 1998 Oct 27;66(8):1014–1020. doi: 10.1097/00007890-199810270-00009. [DOI] [PubMed] [Google Scholar]
  4. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  5. Choy E. H., Panayi G. S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001 Mar 22;344(12):907–916. doi: 10.1056/NEJM200103223441207. [DOI] [PubMed] [Google Scholar]
  6. Danis V. A., Millington M., Hyland V. J., Grennan D. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol. 1995 Feb;99(2):303–310. doi: 10.1111/j.1365-2249.1995.tb05549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Felson D. T., Anderson J. J., Boers M., Bombardier C., Furst D., Goldsmith C., Katz L. M., Lightfoot R., Jr, Paulus H., Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995 Jun;38(6):727–735. doi: 10.1002/art.1780380602. [DOI] [PubMed] [Google Scholar]
  8. Gough A., Faint J., Salmon M., Hassell A., Wordsworth P., Pilling D., Birley A., Emery P. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum. 1994 Aug;37(8):1166–1170. doi: 10.1002/art.1780370809. [DOI] [PubMed] [Google Scholar]
  9. Kroeger K. M., Carville K. S., Abraham L. J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997 Apr;34(5):391–399. doi: 10.1016/s0161-5890(97)00052-7. [DOI] [PubMed] [Google Scholar]
  10. Maini R., St Clair E. W., Breedveld F., Furst D., Kalden J., Weisman M., Smolen J., Emery P., Harriman G., Feldmann M. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939. doi: 10.1016/s0140-6736(99)05246-0. [DOI] [PubMed] [Google Scholar]
  11. McGuire W., Hill A. V., Allsopp C. E., Greenwood B. M., Kwiatkowski D. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 1994 Oct 6;371(6497):508–510. doi: 10.1038/371508a0. [DOI] [PubMed] [Google Scholar]
  12. Olerup O., Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens. 1992 May;39(5):225–235. doi: 10.1111/j.1399-0039.1992.tb01940.x. [DOI] [PubMed] [Google Scholar]
  13. Padyukov L., Hahn-Zoric M., Lau Y. L., Hanson L. A. Different allelic frequencies of several cytokine genes in Hong Kong Chinese and Swedish Caucasians. Genes Immun. 2001 Aug;2(5):280–283. doi: 10.1038/sj.gene.6363771. [DOI] [PubMed] [Google Scholar]
  14. Perrier S., Coussediere C., Dubost J. J., Albuisson E., Sauvezie B. IL-1 receptor antagonist (IL-1RA) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol. 1998 Jun;87(3):309–313. doi: 10.1006/clin.1998.4520. [DOI] [PubMed] [Google Scholar]
  15. Sankaran D., Asderakis A., Ashraf S., Roberts I. S., Short C. D., Dyer P. A., Sinnott P. J., Hutchinson I. V. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation. Kidney Int. 1999 Jul;56(1):281–288. doi: 10.1046/j.1523-1755.1999.00536.x. [DOI] [PubMed] [Google Scholar]
  16. Tarlow J. K., Blakemore A. I., Lennard A., Solari R., Hughes H. N., Steinkasserer A., Duff G. W. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993 May;91(4):403–404. doi: 10.1007/BF00217368. [DOI] [PubMed] [Google Scholar]
  17. Taylor K. D., Plevy S. E., Yang H., Landers C. J., Barry M. J., Rotter J. I., Targan S. R. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology. 2001 May;120(6):1347–1355. doi: 10.1053/gast.2001.23966. [DOI] [PubMed] [Google Scholar]
  18. Thomson W., Harrison B., Ollier B., Wiles N., Payton T., Barrett J., Symmons D., Silman A. Quantifying the exact role of HLA-DRB1 alleles in susceptibility to inflammatory polyarthritis: results from a large, population-based study. Arthritis Rheum. 1999 Apr;42(4):757–762. doi: 10.1002/1529-0131(199904)42:4<757::AID-ANR20>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  19. Turner D. M., Williams D. M., Sankaran D., Lazarus M., Sinnott P. J., Hutchinson I. V. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997 Feb;24(1):1–8. doi: 10.1111/j.1365-2370.1997.tb00001.x. [DOI] [PubMed] [Google Scholar]
  20. Turner D., Grant S. C., Yonan N., Sheldon S., Dyer P. A., Sinnott P. J., Hutchinson I. V. Cytokine gene polymorphism and heart transplant rejection. Transplantation. 1997 Sep 15;64(5):776–779. doi: 10.1097/00007890-199709150-00021. [DOI] [PubMed] [Google Scholar]
  21. Ulfgren A. K., Andersson U., Engström M., Klareskog L., Maini R. N., Taylor P. C. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 2000 Nov;43(11):2391–2396. doi: 10.1002/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  22. Ulfgren A. K., Gröndal L., Lindblad S., Khademi M., Johnell O., Klareskog L., Andersson U. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis. 2000 Jun;59(6):439–447. doi: 10.1136/ard.59.6.439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Weyand C. M., Hicok K. C., Conn D. L., Goronzy J. J. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med. 1992 Nov 15;117(10):801–806. doi: 10.7326/0003-4819-117-10-801. [DOI] [PubMed] [Google Scholar]
  24. Wilson A. G., Symons J. A., McDowell T. L., McDevitt H. O., Duff G. W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195–3199. doi: 10.1073/pnas.94.7.3195. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES